Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. Company
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Real-time Estimate Cboe BZX  -  03:28 2022-11-30 pm EST
198.46 USD   +10.34%
11/23BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA Versus IMBRUVICA in Late-Breaking Oral Session at ASH 2022
AQ
11/22Beigene, Ltd. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
11/22BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA«áVersus IMBRUVICA«áin Late-Breaking Oral Session at ASH 2022
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Business Summary
Logo BeiGene, Ltd.
BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of BrutonÔÇÖs Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers, and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company also has other products in its clinical stage, including BGB-283, BGB-3245, BGB-11417, BGB-A445, BGB-A425, BGB-15025, BGB-A333, BGB-A1217, and BGB-10188. The Company operates offices in 30 countries on five continents, namely the United States, China, Europe, and Australia.

Number of employees : 8 200 people.
Sales per Business
20202021Delta
Pharmaceutical Products308.87100%1 176.28100% +280.83%
USD in Million
Sales per region
20202021Delta
China290.6594.1%517.1744% +77.94%
United States18.235.9%495.2742.1% +2617.06%
Rest of World--163.8513.9%-
USD in Million
Managers
Name Title Age Since
John Oyler Director 53 2010
Xiao Bin Wu President & Chief Operating Officer 59 2021
Julia Wang Chief Financial & Accounting Officer 50 2021
Lai Wang Global Head-Research & Development - 2021
Christiane Langer Senior Vice President-Global Medical Affairs - 2021
Mark Lanasa Chief Medical Officer - 2022
Kevin C. Mannix Senior Vice President-Investor Relations - 2021
Scott Alan Samuels Secretary & Senior Vice President 51 2022
Yan Liu Vice President-Marketing - 2019
Wendy Yan Chief Regulatory Officer & Senior Vice President 55 -
Members of the board
Name Title Age Since
John Oyler Director 53 2010
Michael J. Goller Independent Non-Executive Director 46 2015
Donald W. Glazer Independent Non-Executive Director 76 2013
Ranjeev Krishana Independent Non-Executive Director 47 2014
Qing Qing Yi Independent Non-Executive Director 49 2014
Thomas R. Malley Independent Non-Executive Director 52 2016
Corazon Dating Sanders, Dr. Independent Non-Executive Director 64 2020
Alessandro Riva, Dr. Independent Non-Executive Director 60 2022
Han Dugan, Dr. Independent Non-Executive Director 64 2022
Xiao Dong Wang Non-Executive Director 58 2016
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0.07692 1,349,639,439 1,321,456,238 97.9% 0 0.0% 97.9%
Shareholders
NameEquities%
Baker Bros. Advisors LP 11,668,897 11.3%
HHLR Advisors Ltd. 10,878,366 10.5%
Capital Research & Management Co. (International Investors) 6,591,242 6.36%
PRIMECAP Management Co. 4,734,979 4.57%
Baillie Gifford & Co. 3,209,941 3.10%
Temasek Holdings Pte Ltd. (Investment Management) 3,109,970 3.00%
Invesco Advisers, Inc. 2,690,425 2.59%
Capital Research & Management Co. (Global Investors) 1,828,239 1.76%
Capital Research & Management Co. (World Investors) 1,828,239 1.76%
Fidelity Management & Research Co. LLC 1,399,899 1.35%
Holdings
NameEquities%Valuation
LEAP THERAPEUTICS, INC. (LPTX) 7,348,437 7.42% 6,253,520 USD
Company contact information
BeiGene Ltd.
Zhongguancun Life Science Park
No. 30 Science Park Road
Changping District
Beijing 102206

Phone : +86.10.58958000
Fax : +86.10.58958080
Web : http://www.beigene.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of BeiGene, Ltd.